As noted in a previous blog (see below for link), tofacitinib, an oral Janus Kinase Inhibitor has shown promise as an agent for ulcerative colitis. However, its results thus far for Crohn’s disease (CD) have been discouraging. Another study (Clin Gastroenterol Hepatol 2014; 12: 1485-93) reiterates that message.
In brief, 139 patients with moderate-to-severe active CD were randomly assigned to 3 dosage groups of tofacitinib (1-, 5-, and 15-mg) and compared with placebo. There were no significant differences in response or remission between tofacitinib and the placebo group, though there were reductions in both C-reactive protein and fecal calprotectin among patients given the 15-mg dose.
Related blog posts:
- Tofacitinib -Risks and Benefits in Rheumatoid Arthritis …
- Tofacitinib -a JAK Inhibitor for UC | gutsandgrowth